MaxCyte, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| MXCT | LAB | CTKB | ALERS.PA | CHY.F | CTSO | |
|---|---|---|---|---|---|---|
| Market cap | 143.46M | 243.14M | 764.30M | 265.30M | 1.47B | 14.37M |
| P/E (TTM) | — | — | — | 37.6 | 55.2 | — |
| Forward P/E | -5.6 | -61.6 | 84.0 | 23.3 | — | — |
| Price/book | 0.9 | 0.4 | 2.2 | 1.4 | 15.3 | -19.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −12.57% | −46.49% | +48.63% | +9.56% | −18.93% | −69.53% |
| Today | −4.79% | +0.85% | −1.34% | 0.00% | −0.47% | +0.44% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All MXCT news ›MaxCyte Reports Preliminary Third Quarter 2026 Revenue and Raises Full Year 2026 Revenue Guidance
ROCKVILLE, Md., Oct. 14, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation…
Liontrust Investment Partners Discloses Investment at MaxCyte with 5.03% Stake
Liontrust Investment Partners LLP disclosed a 5.03% beneficial stake in MAXCYTE, INC. common stock. The Schedule 13D was filed on Oct. 15, 2026, and details a series of September sales followed by purchases on Oct. 14. The move brings…
MaxCyte shareholder Liontrust reports 5.033% stake
An investor reports over 5% of MaxCyte (MXCT) after October 14 share purchases. Stock Titan Sales are listed in September and on October 7, 2026, before purchase entries dated October 14, 2026. MaxCyte, Inc. (MXCT) is the issuer in a…
MaxCyte stock rallies on initial Q3 revenue, higher FY26 outlook
MaxCyte MXCT surged ~30.15% to ~$1.26 on Wednesday after the cell-engineering company reported preliminary third-quarter 2026 revenue growth and raised its full-year revenue guidance. According to the press release, preliminary…
MaxCyte expects about 15% H2 core revenue growth
Liberty Energy Inc. Announces Third Quarter 2026 Financial and Operational Results MaxCyte’s revised outlook calls for approximately 15% year-over-year core business revenue growth in the second half of 2026. MaxCyte (MXCT) reported…
Cell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
TradingView Cell-engineering firm MaxCyte's Q3 revenue beats; annual outlook lifted
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net3
- tradingview.com3
- manilatimes.net1
- wboc.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 8 articles, not a forecast.